Skip to main content

Advertisement

SpringerLink
Log in

QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach

  • Original Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

Ibrutinib (IBR) is the choice of drug for the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). IBR has low oral bioavailability of 2.9% owing to its high first pass metabolism. Present study was aimed to develop the nanostructured lipid carriers (NLC) using glyceryl monostearate (GMS) as solid lipid and Capryol™ PGMC as liquid lipid. Plackett-Burman design (PBD) was applied to screen the significant factors; furthermore, these significant factors were subjected to optimisation using Central Composite design (CCD). The size, poly dispersity index (PDI) and entrapment efficiency (E.E.) of the developed NLC were 106.4 ± 8.66 nm, 0.272 ± 0.005 and 70.54 ± 5.52% respectively. Morphological evaluation using transmission electron microscope (TEM) and field emission scanning electron microscope (FESEM) revealed spherical particles. Furthermore, differential scanning calorimetry (DSC) indicates the formation of molecular dispersion of drug in the melted lipid matrix while Powder X-Ray Diffraction (PXRD) studies reveal the absence of crystalline drug peaks in the formulation diffractogram. In-vivo pharmacokinetics of NLC displayed an increase in Cmax (2.89-fold), AUC0-t (5.32-fold) and mean residence time (MRT) (1.82-fold) compared with free drug. Furthermore, lymphatic uptake was evaluated by chylomicron flow blocking approach using cycloheximide (CXI). The pharmacokinetic parameters Cmax, AUC0-t and MRT of NLC without CXI were 2.75, 3.57 and 1.30 folds higher compared with NLC with CXI. The difference in PK parameters without CXI indicates significant lymphatic uptake of the formulation. Hence, NLC can be a promising approach to enhance the oral bioavailability of drugs with high first-pass metabolism.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

Similar content being viewed by others

References

  1. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54(11):2385–91.

    CAS  PubMed  Google Scholar 

  2. Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M. Ibrutinib-a double-edge sword in cancer and autoimmune disorders. J Drug Target. 2016;24(5):373–85.

    CAS  PubMed  Google Scholar 

  3. Smith MR. Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother. 2015;16(12):1879–87.

    CAS  PubMed  Google Scholar 

  4. Qiu Q, Lu M, Li C, Luo X, Liu X, Hu L, et al. Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. AAPS PharmSciTech. 2018;19(8):3571–83.

    CAS  PubMed  Google Scholar 

  5. Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B-cell malignancies to solid tumors. Oncoscience. 2016;3(5–6):147.

    PubMed  PubMed Central  Google Scholar 

  6. Haura EB, Rix U. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J Natl Cancer Inst. 2014;106(9):dju250.

    PubMed  PubMed Central  Google Scholar 

  7. Shakeel F, Iqbal M, Ezzeldin E. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol. 2016;68(6):772–80.

    CAS  PubMed  Google Scholar 

  8. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495(1):439–46.

    CAS  PubMed  Google Scholar 

  9. Garg A, Bhalala K, Tomar DS. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. Int J Pharm. 2017;516(1–2):120–30.

    CAS  PubMed  Google Scholar 

  10. Xie S, Zhu L, Dong Z, Wang Y, Wang X, Zhou W. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomedicine. 2011;6:547.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Gonçalves L, Maestrelli F, Mannelli LDC, Ghelardini C, Almeida A, Mura P. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm. 2016;102:41–50.

    PubMed  Google Scholar 

  12. Mishra DK, Dhote V, Bhatnagar P, Mishra PK. Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research. Drug Deliv Transl Res. 2012;2(4):238–53.

    CAS  PubMed  Google Scholar 

  13. Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733.

    PubMed Central  Google Scholar 

  14. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B. 2013;3(6):361–72.

    Google Scholar 

  15. Nooli M, Chella N, Kulhari H, Shastri NR, Sistla R. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(4):611–7.

    CAS  PubMed  Google Scholar 

  16. Shi X, Song S, Ding Z, Fan B, Huang W, Xu T. Improving the solubility, dissolution, and bioavailability of Ibrutinib by preparing it in a Coamorphous state with saccharin. J Pharm Sci. 2019;108:3020–8.

    CAS  PubMed  Google Scholar 

  17. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83–101.

    Google Scholar 

  18. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Beloqui A, del Pozo-Rodríguez A, Isla A, Rodríguez-Gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J Drug Deliv Sci Technol. 2017;42:144–54.

    CAS  Google Scholar 

  20. Sahu AK, Kumar T, Jain V. Formulation optimization of erythromycin solid lipid nanocarrier using response surface methodology. Biomed Res Int. 2014;2014:1–8.

    Google Scholar 

  21. Lin C-H, Chen C-H, Lin Z-C, Fang J-Y. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017;25(2):219–34.

    CAS  PubMed  Google Scholar 

  22. Radtke M, Müller RH. Nanostructured lipid drug carriers. New Drugs. 2001;2:48–52.

    Google Scholar 

  23. Müller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles. Percutaneous Penetration Enhancers Chem Methods Penetration Enhancement. Springer. 2016:161–85.

  24. Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289–98.

    CAS  PubMed  Google Scholar 

  25. Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech. 2019;20(8):326.

    PubMed  Google Scholar 

  26. Kaithwas V, Dora CP, Kushwah V, Jain S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids Surf B: Biointerfaces. 2017;154:10–20.

    CAS  PubMed  Google Scholar 

  27. Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461(1–2):403–10.

    CAS  PubMed  Google Scholar 

  29. Patwekar SL, Pedewad SR, Gattani S. Development and evaluation of nanostructured lipid carriers-based gel of isotretinoin. Part Sci Technol. 2018;36(7):832–43.

    CAS  Google Scholar 

  30. Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45(2):364–71.

    CAS  PubMed  Google Scholar 

  31. Wu P-S, Lin C-H, Kuo Y-C, Lin C-C. Formulation and characterization of hydroquinone nanostructured lipid carriers by homogenization emulsification method. J Nanomater. 2017;2017:1–7.

    Google Scholar 

  32. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv. 2011;8(10):1341–60.

    CAS  PubMed  Google Scholar 

  33. Kan S, Lu J, Liu J, Wang J, Zhao Y. A quality by design (QbD) case study on enteric-coated pellets: screening of critical variables and establishment of design space at laboratory scale. Asian J Pharm Sci. 2014;9(5):268–78.

    Google Scholar 

  34. Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889–901.

    CAS  Google Scholar 

  35. Yerlikaya F, Ozgen A, Vural I, Guven O, Karaagaoglu E, Khan MA, et al. Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach. J Pharm Sci. 2013;102(10):3748–61.

    CAS  PubMed  Google Scholar 

  36. Kovács A, Berkó S, Csányi E, Csóka I. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the quality by design method. Eur J Pharm Sci. 2017;99:246–57.

    PubMed  Google Scholar 

  37. Beg S, Saini S, Bandopadhyay S, Katare O, Singh B. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of olmesartan medoxomil employing multivariate statistical techniques. Drug Dev Ind Pharm. 2018;44(3):407–20.

    CAS  PubMed  Google Scholar 

  38. Mishra V, Kesharwani P, Amin MC, Iyer A, editors. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Academic Press; 2017.

  39. Xia D, Shrestha N, van de Streek J, Mu H, Yang M. Spray drying of fenofibrate loaded nanostructured lipid carriers. Asian J Pharm Sci. 2016;11(4):507–15.

    Google Scholar 

  40. Gupta B, Poudel BK, Tran TH, Pradhan R, Cho H-J, Jeong J-H, et al. Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers. Pharm Res. 2015;32(9):2912–27.

    CAS  PubMed  Google Scholar 

  41. Martins S, Tho I, Souto E, Ferreira D, Brandl M. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharm Sci. 2012;45(5):613–23.

    CAS  PubMed  Google Scholar 

  42. Esbensen KH, Guyot D, Westad F, Houmoller LP. Multivariate data analysis: in practice: an introduction to multivariate data analysis and experimental design. Multivariate Data Analysis; 2002.

    Google Scholar 

  43. Baumgartner R, Teubl BJ, Tetyczka C, Roblegg E. Rational design and characterization of a nanosuspension for intraoral administration considering physiological conditions. J Pharm Sci. 2016;105(1):257–67.

    CAS  PubMed  Google Scholar 

  44. Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv. 2017;24(1):932–41.

    CAS  PubMed  Google Scholar 

  45. Sharma A, Jaiswal S, Shukla M, Sharma M, Chauhan PMS, Rangaraj N, et al. HPLC–MS-MS method development and validation of antileishmanial agent, S010-0269, in hamster serum. J Chromatogr Sci. 2015;53(9):1542–8.

    CAS  PubMed  Google Scholar 

  46. Bhalekar MR, Upadhaya PG, Madgulkar AR, Kshirsagar SJ, Dube A, Bartakke US. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. Drug Deliv. 2016;23(7):2581–6.

    CAS  PubMed  Google Scholar 

  47. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24(4):381–8.

    CAS  PubMed  Google Scholar 

  48. Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine. 2014;9:1049.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Patel M, Sawant K. A quality by design concept on lipid based nanoformulation containing antipsychotic drug: screening design and optimization using response surface methodology. J Nanomed Nanotechnol. 2017;8(3):1–11.

    Google Scholar 

  50. Chouhan P, Saini T. D-optimal design and development of microemulsion based transungual drug delivery formulation of ciclopirox olamine for treatment of onychomycosis. Indian J Pharm Sci. 2016;78(4):498–511.

    CAS  Google Scholar 

  51. Patil-Gadhe A, Pokharkar V. Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design. Int J Pharm. 2016;501(1–2):199–210.

    CAS  PubMed  Google Scholar 

  52. Instruments M. Zetasizer nano series user manual. MAN0317. 2004;1:2004.

  53. Singh A, Neupane YR, Panda BP, Kohli K. Lipid based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer. J Microencapsul. 2017;34(4):416–29.

    CAS  PubMed  Google Scholar 

  54. Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2015;20(3):320–9.

    CAS  PubMed  Google Scholar 

  55. Su Y-L, Liu H-Z, Guo C, Wang J. Association behavior of PEO–PPO–PEO block copolymers in water or organic solvent observed by FTIR spectroscopy. Mol Simul. 2003;29(12):803–8.

    CAS  Google Scholar 

  56. Han L, Wang T. Preparation of glycerol monostearate from glycerol carbonate and stearic acid. RSC Adv. 2016;6(41):34137–45.

    CAS  Google Scholar 

  57. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1–2):232–43.

    CAS  PubMed  Google Scholar 

  58. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139–51.

    CAS  PubMed  Google Scholar 

  59. Liao H, Gao Y, Lian C, Zhang Y, Wang B, Yang Y, et al. Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems. Int J Nanomedicine. 2019;14:7291–306.

    PubMed  PubMed Central  Google Scholar 

  60. Mishra A, Vuddanda PR, Singh S. Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J Nanotechnol. 2014;2014:1–12.

    Google Scholar 

  61. Baheti A, Srivastava S, Sahoo D, Lowalekar R, Prasad Panda B, Kumar Padhi B, et al. Development and pharmacokinetic evaluation of industrially viable self-microemulsifying drug delivery systems (SMEDDS) for terbinafine. Curr Drug Deliv. 2016;13(1):65–75.

    CAS  Google Scholar 

  62. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702–16.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are thankful to the NIPER-HYD and Department of Pharmaceuticals (DoP) for providing the facilities.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India

    Nagarjun Rangaraj, Sravanthi Reddy Pailla, Saurabh Shah, Shubham Prajapati & Sunitha Sampathi

Authors
  1. Nagarjun Rangaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sravanthi Reddy Pailla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saurabh Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shubham Prajapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sunitha Sampathi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunitha Sampathi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

All Institutional and National guidelines for the care and use of laboratory animals were followed.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 2380 kb).

ESM 2

(DOCX 16 kb).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rangaraj, N., Pailla, S.R., Shah, S. et al. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Deliv. and Transl. Res. 10, 1476–1494 (2020). https://doi.org/10.1007/s13346-020-00803-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-020-00803-7

Keywords

Search

Navigation